Frazier Life Sciences Acquisition Corp. II closes $75M IPO and $3M sponsor private placement

Frazier Life Sciences Acquisition Corp. II

IPO of 7,500,000 Class A ordinary shares at $10.00 per share generated $75,000,000 gross proceeds; offering costs were $4,111,319.
Sponsor Frazier Life Sciences Holdings II, LLC bought 300,000 Class A shares at $10.00 in a $3,000,000 private placement closed simultaneously with the IPO.
$75,000,000 was deposited in a U.S. trust account with Continental Stock Transfer & Trust Company as trustee; cash outside the trust was $1,762,481.
Balance sheet shows $3,000,000 deferred underwriting fee payable plus a $750,000 upfront underwriting discount; accumulated deficit of $1,226,690 as of October 15, 2026.
Company has not selected a business combination target or held substantive talks; it has 24 months from the IPO close to consummate a deal.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.